Related by context. All words. (Click for frequent words.) 78 CCyR 67 Scale EDSS 67 response CCyR 67 Primary endpoints 67 Crohn Disease Activity 66 Secondary endpoints included 66 cytogenetic response 66 Montgomery Asberg Depression 66 Index CDAI 65 prospectively stratified 65 prespecified secondary 65 RECIST Response Evaluation Criteria 65 Kaplan Meier estimates 64 ADCS CGIC 64 morphometric vertebral fractures 64 biochemical relapse 64 annualized relapse 64 Index CDAI score 64 achieved CCyR 64 Solid Tumors criteria 64 achieved ACR# 64 cEVR 63 progression TTP 63 Operative mortality 63 Free Survival PFS 63 DAS# CRP 63 remission CR 63 preintervention 63 plasma HCV RNA 63 Secondary endpoints include 63 Ishak fibrosis score 63 Montgomery Åsberg Depression 63 undetectable HBV DNA 63 postintervention 63 Response Evaluation Criteria 63 QTcF 62 complete cytogenetic response 62 CR nPR 62 Folfox 62 PASI scores 62 irinotecan cisplatin 62 CDAI score 62 glycosylated hemoglobin HbA1c 62 Negative Symptoms 62 Y BOCS 62 MCyR 62 Pharmacokinetic parameters 62 tumor progression TTP 62 SIMPADICO 62 ACR# response 62 Rating Scale MADRS 62 -#.# log# copies mL 62 Scale EDSS score 62 prospectively defined 62 relapsed MM 62 RECIST criteria 62 complete cytogenetic 61 % CI #.#-#.# [003] 61 CRp 61 nonfatal myocardial infarction 61 aspartate aminotransferase AST 61 ug dose 61 evaluable subjects 61 infliximab monotherapy 61 locoregional recurrence 61 sustained virological response 61 Severity Index PASI 61 Expanded Disability Status 61 Severity MSCS score 61 prednisone prednisolone plus 61 underwent surgical resection 61 Solid Tumors RECIST 61 Viral load 61 FluCAM arm 61 IRLS score 61 Score DAS# 61 antiretroviral naïve 61 repeat paracentesis 61 Psoriasis Area 61 mcg BID 61 adefovir treated 61 underwent resection 61 IBDQ 61 secondary efficacy endpoint 61 baseline HbA1c 61 alanine aminotransferase ALT 61 microbiologically evaluable 61 ipsilateral stroke 61 -#.# log# 61 microbiological eradication 61 Global Impression CGI 61 #.#/#.# mmHg [001] 60 postoperative chemotherapy 60 8mg/kg 60 detectable HCV RNA 60 Tumor Response 60 Interrater reliability 60 intraobserver 60 Kaplan Meier analysis 60 hemoglobin A1C HbA1C 60 PSA nadir 60 elevated ALT 60 serum aminotransferase levels 60 REYATAZ r arm 60 Sustained virologic response 60 DAS# remission 60 baseline PASI 60 baseline A1C 60 advanced adenoma 60 Fibromyalgia Impact Questionnaire 60 underwent percutaneous coronary 60 RECORD1 60 PREZISTA r arm 60 angiographic restenosis 60 % Confidence Interval 60 CIMZIA TM certolizumab pegol 60 A1c levels 60 endoscopic remission 60 HbA1C 60 sustained virologic response 60 XIENCE V PROMUS Stent 60 daily Infergen 60 #mg QD [002] 60 CDAI 60 severe exacerbations 60 MADRS score 60 log# copies mL 60 Capacity FVC 60 lopinavir r arm 60 stage IIIb IV 60 debulking surgery 60 HBeAg seroconversion 59 estimated glomerular filtration 59 mean baseline A1C 59 mCi kg 59 urine albumin 59 PSADT 59 confidence intervals CIs 59 Hb A1C 59 SVR# 59 mucosal healing 59 NWEA MAP 59 oxycodone CR 59 definite stent thrombosis 59 sUA levels 59 workhorse lesions 59 Pharmacodynamic 59 HDRS 59 GERD symptom 59 binary restenosis 59 log# IU mL 59 ACR# ACR# 59 HOMA IR 59 PROCTOCORT ® Suppository Hydrocortisone 59 mcg QD 59 certolizumab 59 hemoglobin A1c HbA1c 59 Alzheimer Disease Assessment 59 glycated hemoglobin levels 59 Sustained Virological Response 59 nonfatal MI 59 SEER registries 59 XIENCE V demonstrated 59 pCR 59 PLX STROKE targeting 59 Major Adverse Cardiac 59 PCWP 59 undetectable viral 59 ARB telmisartan 59 Scale cognitive subscale 59 mg QD 59 achieved PASI 59 HSCT 59 XIENCE V vs. 59 statistical significance p 59 Efficacy endpoints 59 HAQ DI 59 DAS# scores 59 Secondary endpoints 59 recovery CRp 59 specific antigen PSA 59 tipranavir r 59 Xelox 59 Left Ventricular Ejection Fraction 59 primary patency 59 HbA 1c levels 59 lactate dehydrogenase LDH 59 events MACE 59 free survival PFS 59 deep venous thromboses 59 Brief Psychiatric 58 aminotransferase ALT 58 NMIBC 58 vincristine doxorubicin 58 TAXUS p value 58 Median progression 58 mg BID dose 58 ipsilateral breast 58 receiving golimumab 58 quantitative coronary angiography 58 Events MACE 58 mL/min/#.# m 2 58 WOMAC pain 58 Kaplan Meier 58 postprocedure 58 SUVmax 58 interquartile range 58 ADAS Cog 58 plus methotrexate 58 anthracycline taxane 58 CR CRu 58 sUA 58 DLQI 58 moderately emetogenic 58 recombinant PSMA vaccine 58 galiximab 58 Secondary efficacy endpoints 58 hemoglobin A1c levels 58 HER2 expression 58 CNS LS 58 -#.# mg dL [001] 58 FUSILEV enhances 58 biochemical recurrence 58 ALT elevation 58 UPDRS scores 58 Hormone Refractory Prostate Cancer 58 fasting plasma glucose FPG 58 partial remissions 58 disease progression TTP 58 Change PGIC 58 hours postdose 58 ADAS cog 58 seroprotection 58 Skin sterol 58 ACTEMRA TM 58 sensitivity specificity 58 Fasting blood glucose 58 evaluable 58 plus dexamethasone 58 azilsartan medoxomil 58 EDSS scores 58 spirometric 58 Visual Analogue Scale VAS 58 NNT = 58 serum phosphorous 58 Negative Syndrome 58 corticosteroid dose 58 median survivals 58 Myocardial Infarction Study 58 XL# administered orally 58 nicardipine 58 R# #mg BID 58 achieved sustained virologic 58 plus MTX 58 mitoxantrone plus 58 #mg dose [002] 58 neurologic progression 58 preoperative PSA 58 #mg QD [001] 58 #mg/day [002] 58 angiographic outcomes 58 Tasigna prolongs 58 Median PFS 58 urinary N telopeptide 58 nadroparin 58 mg BID 58 linaclotide treated 58 ischemia driven 58 clinicopathological features 58 docetaxel pretreated 58 PASI score 58 glycated hemoglobin HbA1c 58 ACR Pedi 58 haematologic 58 receiving highly emetogenic 57 Median survival 57 calculated creatinine clearance 57 revascularized 57 Institute CMM Capability 57 EURIDIS 57 Common Toxicity Criteria 57 low dose Iluvien 57 Complete Remission 57 Score TOS 57 mean ± SEM 57 MoxDuo TM IR 57 PERMP 57 Cystic Fibrosis Questionnaire Revised 57 Kaplan Meier estimate 57 Decompensated Heart Failure 57 #μg [002] 57 VcMP 57 Flu Cy 57 lumbar spine BMD 57 neuropathy sensory 57 Rate ORR 57 neoadjuvant 57 hematopoietic cancers 57 naïve HCV 57 androgen suppression 57 ARCOXIA 57 echocardiographic parameters 57 HBV DNA levels 57 Partial Response 57 abacavir lamivudine 57 dalteparin 57 #mg/day [001] 57 bortezomib refractory 57 median PFS 57 ACR# responses 57 FDG PET scans 57 Lupuzor ™ 57 baseline LDH 57 HbA1C levels 57 serum urate 57 adenoma recurrence 57 mg ustekinumab 57 Platelet counts 57 metastatic GIST 57 AUA Symptom Score 57 ITU algorithms PAMS 57 IMPACT DCM 57 LDH lactate dehydrogenase 57 treatment naive genotype 57 Mean Symptom Complex 57 Cardiac Resynchronization 57 rosuvastatin #mg 57 intravascular hemolysis 57 Maturity Model Level 57 mcg albinterferon alfa 2b 57 mg TID 57 arterial thromboembolic events 57 histologically confirmed 57 FOLFOX6 57 microgram kg 57 unfractionated heparin UFH 57 4mg/kg 57 NIS LL 57 UPDRS motor 57 refractory ischemia 57 p = NS 57 Erythropoietic therapies may 57 lymphocyte count 57 demonstrated clinically meaningful 57 epoetin alpha 57 prespecified 57 dosing cohorts 57 LDL triglycerides 57 Solid Tumors 57 response pCR 57 Stent thrombosis 57 TLUS 57 dyslipidemia hypertension diabetes 57 NIHSS score 57 mg/m2 dose 57 pegylated interferon alfa 2b 57 IELT 57 Chemotherapy Improves 57 inhospital 57 mg p = 57 Persistent Sleep 57 desvenlafaxine succinate 57 EDSS score 57 FOLFOX4 57 graft occlusion 57 nonmetastatic 57 Follicular Lymphoma 57 liver histology 57 hip BMD 57 STRIDE PD 57 reduce serum phosphate 57 extracolonic findings 57 undetectable HCV RNA 57 achieving PASI 57 visceral metastases 57 cisplatin gemcitabine 57 serum phosphate 57 Partial Responses 57 clinically meaningful improvement 57 postoperative mortality 57 atorvastatin #mg 57 Virologic 57 platelet reactivity 57 EBMT criteria 57 nondiabetic patients 57 undergone radical prostatectomy 57 EGFR TKI 57 diameter stenosis 57 posttreatment 57 #Gy 57 moderate renal impairment 57 periprocedural 57 BMI z 57 multigene expression test 57 Ejection Fraction 57 recurrent myocardial infarction 57 IOP lowering 57 hsCRP levels 57 pT3 57 REYATAZ r 57 nodular partial response 57 FOLFIRI alone 57 cTnT levels 57 #mg BID [003] 56 bronchial hyperresponsiveness 56 mTSS 56 Bayer HealthCare Onyx Pharmaceuticals 56 SELENA SLEDAI 56 BPH Symptom Score 56 abdominal pain abdominal discomfort 56 perioperative mortality 56 invasive aspergillosis 56 carotid intima media 56 Visual Analog Scale 56 dosing cohort 56 CIMZIA ™ 56 histologic subtype 56 baseline FEV 56 receiving INTRON 56 BENICAR HCT 56 -#.# mg dL [002] 56 completely resected 56 EmbraceAC 56 CHD CVD 56 Pharmacokinetic 56 #.#ng/ml 56 adjuvant GIST 56 q#h 56 Arch Intern Med 56 PRADAXA #mg 56 CSBM 56 Active Ulcerative Colitis 56 System IPSS 56 % CI #.#-#.# [005] 56 ADHD RS 56 erythrocyte sedimentation rate 56 Demonstrate Significant 56 achieved sustained virological 56 myocardial infarction ventricular fibrillation 56 #mg BID [001] 56 p = #.# [003] 56 QIDS SR 56 patients evaluable 56 PSQI 56 Adjusted EBITDAR margin 56 3mg/kg 56 recurrent venous thromboembolism 56 Telik logo TELINTRA 56 ratio ICER 56 EGFR mutation positive 56 systemic embolism 56 R0 resection 56 Stage IIB 56 HAM D# 56 Vidaza ® 56 REMINYL ® 56 plus prednisone 56 postdose 56 serum clusterin levels 56 Pegasys plus Copegus 56 multicenter multinational 56 EMBLEM TM 56 albumin excretion rate 56 Engerix B 56 glycosylated hemoglobin levels 56 cobiprostone 56 mm Hg diastolic 56 Ceplene/IL-2 56 Inventory BPI 56 repeat revascularization 56 dose escalation phase 56 tapentadol ER 56 receiving concomitant corticosteroids 56 virologic failure 56 virologic response 56 REVIVE Diabetes 56 abnormal p# biomarker 56 angiography intravascular ultrasound IVUS 56 ExTRACT TIMI 56 Patients Receiving 56 Zometa hazard 56 YMRS 56 6MWD 56 HBeAg negative patients 56 univariate 56 budesonide pMDI 56 ADHD Rating Scale 56 BARACLUDE ® 56 Postoperative complications 56 doxorubicin cyclophosphamide 56 reinfarction 56 resected pancreatic cancer 56 coronary stenosis 56 recurrent VTE 56 nonvertebral fractures 56 Maturity Model Integration 56 placebo p = 56 CI -#.# 56 intima media thickness 56 Sensitivity specificity 56 interferon ribavirin 56 Ocular Surface Disease 56 PANSS total 56 activated partial thromboplastin 56 octreotide LAR 56 LV dysfunction 56 receiving Vectibix monotherapy 56 aplastic anemia AA 56 Acneform rash occurred 56 weekly CSBMs 56 paclitaxel cisplatin 56 STRATEGY FOR AN OPEN 56 attain statistical significance 56 Treatment Naive Patients 56 Forced Vital 56 Platinol ® cisplatin 56 genotypic resistance 56 prior chemotherapy regimens 56 Adenomas 56 NIH CPSI 56 lung esophageal 56 preoperative chemotherapy 56 DAS# [002] 56 HF hospitalization 56 IPSS 56 clodronate 56 mcg kg REBETOL 56 viral kinetics 56 pretreatment serum 56 prospective observational studies 55 5 FU leucovorin 55 bone marrow reticulin deposition 55 achieved statistical significance 55 placebo dexamethasone 55 hemagglutination inhibition HAI 55 asymptomatic carotid stenosis 55 mg subcutaneous 55 Castration Resistant Prostate Cancer 55 meta regression 55 alfa 2a 55 Quirky chanteuses Florence 55 cytogenic 55 CSBMs 55 Q#IR 55 Health Assessment Questionnaire 55 % CI #.#-#.# [007] 55 ® emtricitabine 55 multivariable Cox 55 methotrexate monotherapy 55 symptomatic VTE 55 Hamilton Anxiety Scale 55 Breslow thickness 55 leukocyte count 55 % CI #.#-#.# [008] 55 x ULN 55 creatinine ratio 55 HBeAg 55 Overnight Repurchase 55 KRAS mutations occur 55 glycated hemoglobin 55 EGFr expressing metastatic colorectal 55 underwent CABG 55 REMICADE monotherapy 55 FluCAM 55 multivariate Cox 55 ADCS ADL 55 colorectal adenoma 55 mg qd 55 cells μL 55 pretest probability 55 mm Stent 55 mg kg belimumab 55 oral prednisolone 55 Brief Pain 55 serum transaminases 55 virological response 55 overnight polysomnography 55 ug kg 55 MACCE 55 Erectile function 55 Fasting plasma glucose 55 Timed Walk 55 estramustine 55 maximal treadmill 55 null responder HCV 55 coronary revascularisation 55 locoregional control 55 baseline serum creatinine 55 #rd Annual CTRC 55 leucopenia 55 arterial stenosis 55 graft dysfunction 55 5 Fluorouracil 55 ertapenem 55 Cancer Incidence Mortality 55 Outcome Measures 55 IU ml 55 Functional Outcomes 55 Score IPSS 55 PegIFN RBV 55 chemoradiation therapy 55 SSRI SNRI 55 TAXUS Liberte Long 55 F FDG PET 55 deCODE AF TM 55 mg administered orally 55 axillary lymph node 55 myocardial viability 55 hematological parameters 55 Nesiritide 55 noninferior 55 mg kg Hematide 55 #.#mg/dL 55 timepoints 55 intradermal injections 55 adalimumab Humira 55 CIMZIA TM 55 DLTs 55 interquartile range IQR 55 mL/min/#.# m2 55 refractory chronic lymphocytic 55 ribavirin RBV 55 anaphylactic reactions bronchospasm 55 Demonstrated Significant 55 papillary renal cell carcinoma 55 dose pravastatin 55 HIV HCV coinfected 55 BEXXAR Therapeutic Regimen 55 severe neutropenia 55 carboplatin chemotherapy 55 novel VDA molecule 55 exhaled NO 55 recurrent ischemia 55 Key secondary endpoints 55 CK # plasma 55 TURBT 55 underwent liver transplantation 55 lumen diameter 55 Raptiva r 55 tirofiban 55 adjunctive placebo 55 complete Early Virological 55 undetectable virus HCV 55 secondary efficacy endpoints 55 cisplatin vinorelbine 55 CIN2 + 55 aspartate aminotransferase 55 elevated transaminases 55 Adjuvant Treatment 55 Phase III AFFIRM 55 GP IIb IIIa inhibitors 55 clinically evaluable 55 clinicopathologic 55 GOUT 55 HbA1c levels 55 biopsy Gleason 55 radiographic progression 55 Injury Severity Score 55 posttransplant 55 VELCADE melphalan 55 hemodynamic measurements 55 intravenous bolus 55 mesalamine granules 55 JEWELRY Down 55 X ULN 55 preoperative intraoperative 55 Histological 55 resectable pancreatic cancer 55 receiving ISENTRESS 55 generalized edema 55 Main Outcome Measure 55 advanced adenomas 55 MAGE A3 ASCI 55 Scale PANSS 55 undergoing coronary angiography 55 Trouble Tracker Index 55 CORE OM 55 retrospectively analyzed 55 â ‰ ¥ 55 mcg Albuferon 55 abnormal cytology 55 TAXUS Express Stent 55 IR Cysteamine 55 mild renal impairment 55 multivariable adjusted 55 cytogenetic responses 55 IIIa inhibitor 55 undergo percutaneous coronary 55 tolerability pharmacokinetics 55 reactogenicity 55 Cystatin C 55 rapid virologic response 55 NIHSS 55 APPRAISE 54 highly emetogenic 54 Hemoglobin A1c 54 creatine kinase MB 54 spontaneous bowel movements 54 dapagliflozin plus 54 preoperatively 54 pyrexia mucositis sepsis febrile 54 multivariate adjustment 54 Teriflunomide 54 peripheral sensory neuropathy 54 Hb A1c 54 SGRQ 54 #mg ATC 54 PORxin TM platforms 54 prospectively enrolled 54 interstitial brachytherapy 54 comparator arm 54 deCODE ProstateCancer TM 54 Prospective Randomized 54 myocardial necrosis 54 undergoing CABG 54 tumor histology 54 FOLFOX4 alone 54 malignancy HCM 54 cerebrovascular events 54 doxorubicin docetaxel 54 BRCA2 mutation carriers 54 dacarbazine chemotherapy 54 mg kg dose 54 Histologic 54 intact parathyroid hormone 54 MMSE score 54 nonsignificant difference 54 cytoreduction 54 SCr 54 Rating Scale BPRS 54 venous thromboembolic disease 54 Symptom severity 54 DES implantation 54 heFH 54 RGT arm 54 Circulating tumor cells 54 venlafaxine XR 54 log# reduction 54 curative resection 54 Univariate 54 Relapsing Multiple Sclerosis 54 oral levofloxacin 54 cardiovascular hospitalizations 54 interobserver 54 BPH symptom 54 gemcitabine carboplatin 54 resuscitated cardiac arrest 54 ADVANCE ILLUMINATE 54 #mg/m# [002] 54 CHD mortality 54 interrater reliability 54 briakinumab 54 fructosamine 54 stent binary restenosis 54 Bronchopulmonary Dysplasia 54 RECIST 54 #q# deletion syndrome 54 oral FTY# 54 Peginterferon Alfa 2a 54 death reinfarction 54 ER CHOP 54 HCV RESPOND 2 54 International Prognostic Scoring 54 serum potassium 54 TNSS 54 ACUITY trial 54 Receives URAC 54 macrovascular events 54 plus OBT 54 non squamous histology 54 recurrent metastatic 54 ALT normalization 54 WBRT alone 54 Rating Scale IRLS 54 Invasive Breast Cancer 54 zoledronic acid Reclast 54 mcg kg 54 troponin T 54 recurrent glioblastoma multiforme 54 TEAEs 54 bepotastine besilate nasal spray 54 clinico pathological 54 hip femoral neck 54 carotid IMT 54 SPIRIT FIRST 54 statistically significant efficacy 54 rehospitalization 54 humanized interleukin 6 54 mIU ml 54 UNCERTAINTY OF FUTURE FINANCIAL 54 pain palliation 54 cervical intraepithelial neoplasia 54 PSMA ADC 54 WOMAC scores 54 ST Segment Elevation 54 Non inferiority 54 neutrophil counts 54 histological subtype 54 Hereafter Inception Iron Man 54 GetGoal Phase III 54 INVEGA ® 54 pharmacodynamic PD 54 salmeterol fluticasone propionate 54 serum prostate 54 metastatic CRC 54 FOLPI 54 serum HBV DNA 54 titrated glipizide plus 54 EAL2 + 54 oral allopurinol 54 mg/m2/day 54 neutropenia dehydration dyspnea 54 flutamide 54 DOXIL 54 CRESTOR #mg 54 International Prostate Symptom 54 Cardiotoxicity 54 CI #.#-#.# [001] 54 Reduces Mortality 54 BRIM3 54 permanently discontinue Vectibix 54 NCCN Updates 54 evaluable patients 54 radiographic outcomes 54 asymptomatic PAD 54 PROTECT II 54 ritonavir boosted 54 Doxil ® 54 Angiographic 54 standard chemotherapy regimen 54 Neuropsychiatric Inventory NPI 54 HbA 1c 54 Pulse CO Oximetry Pulse 54 plasma uric acid 54 Baseline characteristics 54 plus COPEGUS 54 lymphocytosis 54 Thrombolysis 54 alanine transaminase ALT 54 median CD4 54 oral rivaroxaban 54 distant metastasis 54 hormone receptor status 54 Renal Cell Carcinoma RCC 54 iniparib BSI 54 laboratory abnormalities 54 Unstable Angina 54 HI titers 54 WOMAC TM 54 -#.# ± [002] 54 retrospective cohort 54 prospectively evaluated 54 insulin detemir 54 placebo p 54 HES CEL 54 Main Outcome Measures 54 Rating Scale UPDRS 54 proximal DVT 54 left ventricular diastolic 54 NYHA functional class 54 nonfatal myocardial infarction MI 54 Phase 2b Clinical Trial 54 Hazard Ratio HR 54 Disease Activity 54 postoperative AF 54 mmHg p = 54 cyclophosphamide methotrexate 54 COMBIVIR 54 odds ratios ORs 54 symptomatic carotid stenosis 54 serum PSA 54 Emil Protalinski Published 54 prospective multicentre 54 OGTT 54 placebo fluoxetine 54 μg dose 54 viral tropism 54 plasma leptin 54 rimonabant #mg/day 54 μmol L 54 IRLS 54 tolterodine ER 54 q#d 54 primary percutaneous coronary 54 nmol l 54 nonsignificant 54 Accelerated Partial Breast Irradiation 54 dacarbazine DTIC 54 logMAR 54 nasal symptom 54 LVEF 54 CYT# potent vascular disrupting 54 glycosylated hemoglobin 54 estimated GFR 54 quetiapine risperidone 54 refractory NSCLC 54 tipranavir ritonavir 54 NATRECOR R 54 alanine aminotransferase 54 coronary revascularization 54 univariate analysis 54 drotrecogin alfa activated 54 adjuvant systemic 54 EGFR expressing mCRC 54 conditional logistic regression 54 postoperative complication 54 stroke myocardial infarction 54 Seattle Angina Questionnaire 54 CK # plasma concentrations 54 GOVERNMENT MEETINGS 53 nonadherence 53 CIN3 53 expiratory flow 53 Arterial stiffness 53 ARCALYST ® 53 UACR 53 urate lowering therapy 53 experienced virologic failure 53 serum thyroglobulin 53 febrile neutropenia 53 nonfasting triglyceride levels 53 atazanavir ritonavir 53 Physical Function 53 weekly subcutaneous injections 53 avosentan 53 Febrile neutropenia 53 antibody titer 53 cerebrovascular accidents 53 serum CRP 53 chlorambucil 53 PEG IFN 53 peg interferon 53 nonfatal stroke 53 serologically active patients 53 Institute CMMI Capability 53 Common Terminology Criteria 53 undergone splenectomy 53 SEI Software 53 COPD exacerbation 53 nucleoside naive patients 53 everolimus eluting stents 53 Neuropsychiatric Inventory 53 CYP#A# CYP#D# 53 salmeterol fluticasone 53 recurrent malignant glioma 53 allogeneic HSCT 53 symptomatic intracranial hemorrhage 53 -#.# USD JPY [002] 53 CLL SLL 53 gadolinium enhancing lesions 53 advanced neoplasia 53 % CI #.#-#.# [006] 53 T1c 53 ANCOVA 53 Pegasys ® 53 Randomized Phase II 53 piperacillin tazobactam 53 MGd 53 peginterferon 53 lipid lowering agents 53 serum uric acid 53 hemoglobin A1C 53 #.#g/day 53 acute STEMI 53 hypophosphatemia 53 CI #.#-#.# [002] 53 KRAS mutant tumors 53 convergent validity 53 #ng/ml 53 Preska imposed 53 mean baseline HbA1c 53 Edge STudy 53 CrCl 53 Tumor shrinkage 53 serum uric acid sUA 53 lactate dehydrogenase 53 pT2 53 lowest tertile 53 CIBIC plus 53 Sentinel Lymph Node 53 EUS FNA 53 ENDEAVOR II 53 ZOLINZA 53 exploratory endpoints 53 Hypotension 53 confidence interval #.#-#.# 53 Carotid Revascularization Endarterectomy vs. 53 mcg linaclotide 53 NCCTG N# 53 blinded randomized placebo controlled 53 serum phosphorus 53 hematologic toxicity 53 thoracoscopic lobectomy 53 headache nasopharyngitis 53 Bone Metastases 53 Kaplan Meier method 53 QM MSP 53 Soriatane R acitretin capsules 53 Payable Oct